[go: up one dir, main page]

BR0016482A - Método para melhorar a compressibilidade de um superdesintegrante, obter um complexo de preparado de droga superdesintegrante altamente compatìvel , superdesintegrante aumentado e sua forma de dosagem sólida - Google Patents

Método para melhorar a compressibilidade de um superdesintegrante, obter um complexo de preparado de droga superdesintegrante altamente compatìvel , superdesintegrante aumentado e sua forma de dosagem sólida

Info

Publication number
BR0016482A
BR0016482A BR0016482-8A BR0016482A BR0016482A BR 0016482 A BR0016482 A BR 0016482A BR 0016482 A BR0016482 A BR 0016482A BR 0016482 A BR0016482 A BR 0016482A
Authority
BR
Brazil
Prior art keywords
super
disintegrant
particles
compressibility
improve
Prior art date
Application number
BR0016482-8A
Other languages
English (en)
Inventor
John Staniforth
Original Assignee
Mendell Co Inc Edward
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mendell Co Inc Edward filed Critical Mendell Co Inc Edward
Publication of BR0016482A publication Critical patent/BR0016482A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)

Abstract

"MéTODO PARA MELHORAR A COMPRESSIBILIDADE DE UM SUPERDESINTEGRANTE, PARA OBTER UM COMPLEXO DE PREPARADO DE DROGA SUPERDESINTEGRANTE ALTAMENTE COMPATìVEL, SUPERDESINTEGRANTE AUMENTADO E FORMA DE DOSAGEM SóLIDA". Onde o método é compreendido por: a) abrir temporariamente ditas partículas; e b) adicionar um agente aumentador que aumente as propriedades do superdesintegrante em relação às partículas não modificadas do superdesintegrante, c) reduzir a elasticidade de ditas partículas de desintegrante tornando o núcleo de ditas partículas mais hidrofóbico; sendo ditas partículas do superdesintegrante selecionadas do grupo consistindo de materiais de amido e materiais celulósicos ou do grupo consistindo de carboximetilamido sódico reticulado e de carboximetilcelulose sódica reticulada.
BR0016482-8A 1999-12-06 2000-12-06 Método para melhorar a compressibilidade de um superdesintegrante, obter um complexo de preparado de droga superdesintegrante altamente compatìvel , superdesintegrante aumentado e sua forma de dosagem sólida BR0016482A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16917499P 1999-12-06 1999-12-06
PCT/US2000/032989 WO2001039746A1 (en) 1999-12-06 2000-12-06 Pharmaceutical superdisintegrant

Publications (1)

Publication Number Publication Date
BR0016482A true BR0016482A (pt) 2002-12-24

Family

ID=22614504

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0016482-8A BR0016482A (pt) 1999-12-06 2000-12-06 Método para melhorar a compressibilidade de um superdesintegrante, obter um complexo de preparado de droga superdesintegrante altamente compatìvel , superdesintegrante aumentado e sua forma de dosagem sólida

Country Status (11)

Country Link
US (2) US6660303B2 (pt)
EP (1) EP1244428A1 (pt)
KR (1) KR20020062323A (pt)
AU (2) AU771440B2 (pt)
BR (1) BR0016482A (pt)
CA (1) CA2393231A1 (pt)
HU (1) HUP0301333A3 (pt)
IL (1) IL150053A0 (pt)
MX (1) MXPA02005562A (pt)
NO (1) NO20022645L (pt)
WO (1) WO2001039746A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0204771D0 (en) * 2002-02-28 2002-04-17 Phoqus Ltd Fast disintegrating tablets
AU2003256284A1 (en) * 2002-06-20 2004-01-06 Orapharma, Inc. Rapidly disintegrating formulations for treating or preventing mucositis
SI21221A (sl) * 2002-06-21 2003-12-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Hitro razpadljive tablete
US20040265375A1 (en) * 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
AU2004296877A1 (en) * 2003-12-09 2005-06-23 Incyte Corporation Dosing methods for ss-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine antiviral therapy
DE602005008721D1 (de) * 2004-03-10 2008-09-18 Ranbaxy Lab Ltd Verfahren zur herstellung von festen dosierformen von amorphem valganciclovir-hydrochlorid
US20050220865A1 (en) * 2004-04-02 2005-10-06 Koleng John J Compressed composition comprising magnesium salt
JP2007532623A (ja) * 2004-04-12 2007-11-15 ファイザー・プロダクツ・インク 破裂型多重粒子中の味マスキング薬物
ES2550626T5 (es) * 2005-02-25 2019-01-15 Takeda Pharmaceuticals Co Método para producir gránulos
JP2009501801A (ja) * 2005-07-18 2009-01-22 ホライゾン セラピューティクス， インコーポレイテッド イブプロフェンとファモチジンとを含有する医薬およびその投与
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
US8067451B2 (en) * 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
US11116728B2 (en) 2006-11-30 2021-09-14 Bend Research, Inc. Multiparticulates of spray-coated drug and polymer on a meltable core
WO2008065504A1 (en) * 2006-11-30 2008-06-05 Pfizer Products Inc. Multiparticulates of spray-coated drug and polymer on a meltable core
WO2008079343A2 (en) * 2006-12-21 2008-07-03 Mallinckrodt Inc. Composition of and method for preparing orally disintegrating tablets containing a high dose of pharmaceutically active ingredients
ES2758624T3 (es) * 2009-02-12 2020-05-06 Fuji Chem Ind Co Ltd Composición de partículas desintegrantes y material de desintegración rápida moldeado por compresión que comprende la misma
WO2010107507A1 (en) * 2009-03-20 2010-09-23 Incube Labs, Llc Solid drug delivery apparatus, formulations and methods of use
US20100285164A1 (en) * 2009-05-11 2010-11-11 Jrs Pharma Orally Disintegrating Excipient
US20160008310A1 (en) * 2014-07-11 2016-01-14 Azanta A/S Misoprostol dispersible tablet
TN2017000003A1 (en) * 2014-07-11 2018-07-04 Azanta Danmark As Misoprostol dispersible tablet.
EP4110263A4 (en) * 2020-02-27 2024-04-17 Henkel AG & Co. KGaA PERSONAL CARE PRODUCT AND METHOD FOR PRODUCING A PERSONAL CARE PRODUCT BY A GENERATIVE PROCESS
CN112618503B (zh) * 2021-01-20 2022-04-15 天津市中央药业有限公司 头孢地尼分散片
CN118903036B (zh) * 2024-10-10 2025-03-04 华夏罕见病药物研发(山东)有限公司 一种含尿苷的组合物的制备方法及其在治疗发育性癫痫性脑病50型中的应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3141875A (en) 1961-03-15 1964-07-21 Fmc Corp Crystallite aggregates disintegrated in acid medium
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
US4772473A (en) * 1986-06-16 1988-09-20 Norwich Eaton Pharmaceuticals, Inc. Nitrofurantoin dosage form
US4910023A (en) * 1988-06-09 1990-03-20 Warner-Lambert Company Drug in combination with flavor masking agent and method for making same
HU203041B (en) 1989-03-14 1991-05-28 Egyt Gyogyszervegyeszeti Gyar Process for producing pharmaceutical compositions of controlled releasing factor containing nifedipin
US5468286A (en) * 1989-10-25 1995-11-21 National Starch And Chemical Investment Holding Corporation Enzymatically debranched starches as tablet excipients
IT1241417B (it) * 1990-03-06 1994-01-14 Vectorpharma Int Composizioni terapeutiche a rilascio controllato di farmaci supportatisu polimeri reticolati e rivestiti con film polimerici,e loro processodi preparazione
CA2041774C (en) 1990-11-27 1994-04-19 Mircea A. Mateescu Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
US5215757A (en) * 1991-03-22 1993-06-01 The Procter & Gamble Company Encapsulated materials
US5272191A (en) 1991-08-21 1993-12-21 Fmc Corporation Cold water soluble films and film forming compositions
AU668198B2 (en) 1992-07-24 1996-04-26 Labopharm (Barbados) Limited Cross-linked polyhydroxylic material for enzymatically controlled drug release
US5616343A (en) 1993-03-25 1997-04-01 Labopharm, Inc. Cross-linked amylose as a binder/disintegrant in tablets
US6106865A (en) 1995-01-09 2000-08-22 Edward Mendell Co., Inc. Pharmaceutical excipient having improved compressibility
IL116674A (en) 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5948438A (en) 1995-01-09 1999-09-07 Edward Mendell Co., Inc. Pharmaceutical formulations having improved disintegration and/or absorptivity
US5733578A (en) 1995-11-15 1998-03-31 Edward Mendell Co., Inc. Directly compressible high load acetaminophen formulations
TW430561B (en) * 1995-12-20 2001-04-21 Gea Farmaceutisk Fabrik As Rapid release tablet composition comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet
CA2217238C (en) 1997-10-24 2005-09-20 Louis Cartilier Cross-linked cellulose as a tablet excipient

Also Published As

Publication number Publication date
EP1244428A1 (en) 2002-10-02
AU2004202515A1 (en) 2004-07-01
US20020068084A1 (en) 2002-06-06
AU771440B2 (en) 2004-03-25
US20050100600A1 (en) 2005-05-12
WO2001039746A1 (en) 2001-06-07
KR20020062323A (ko) 2002-07-25
HUP0301333A3 (en) 2005-06-28
CA2393231A1 (en) 2001-06-07
NO20022645D0 (no) 2002-06-05
AU2061401A (en) 2001-06-12
IL150053A0 (en) 2002-12-01
MXPA02005562A (es) 2004-09-10
HUP0301333A2 (hu) 2004-05-28
US6660303B2 (en) 2003-12-09
NO20022645L (no) 2002-08-01

Similar Documents

Publication Publication Date Title
BR0016482A (pt) Método para melhorar a compressibilidade de um superdesintegrante, obter um complexo de preparado de droga superdesintegrante altamente compatìvel , superdesintegrante aumentado e sua forma de dosagem sólida
BR9915964A (pt) Composição farmacêutica, forma de dosagem oral da mesma, processo de preparar uma composição farmacêutica, método de tratar uma condição ou um distúrbio onde o tratamento com um bloqueador do receptor de aldosterona é indicado e uso de eplerenona micronizada e de um material veìculo celulósico
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
ES2190075T3 (es) Formulaciones farmaceuticas solidas que contienen una mezcla fisica de sulfoalquil-eter-ciclodextrina y un agente terapeutico.
BR9811249A (pt) Nova formulação para inalação; apresentando densidade volumétrica, quando derramada, de 0,20 à 0,38g/ml, processo para preparação de formulação e uso da mesma
BR9507164A (pt) Composiçao farmacêutica em forma de gel para o tratamento de distúrbios da pele processo de tratamento de pele e uso de uma combinaçao de um agente gelificante de polimero e um alcanol inferior de etil hidroxietil celulose e de um alcanol inferior
BR0009759A (pt) Formulação agroquìmica na forma sólida granular, e, métodos para preparação de uma mistura de pulverização e para tratamento de plantas
KR900012606A (ko) 이중 정제
BR0116945A (pt) Uma preparação para prevenção de restenose
BR0115847A (pt) Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos
BRPI0112725B8 (pt) composição de verniz para unhas.
BR0013720A (pt) Formulação em pelota de liberação controlada
BR0111335A (pt) Derivado de quinazolina, processo para a preparação de um derivado de, quinazolina, composição farmacêutica, e, uso de um derivado de quinazolina
KR910004180A (ko) 저작성 약제학적 정제를 제조하기 위한 회전과립화 공정 및 맛을 은폐하기 위한 피복공정
BR9811987A (pt) Comprimidos de metil celulose de rápida desintegração
HUP0000141A2 (hu) Eljárás legfeljebb 90 tömeg% gyógyhatású anyagot tartalmazó pelletek előállítására
BR0015580A (pt) Composições analgésicas contendo buprenorfina
BR9714379A (pt) Tablete detergente revestido
BR9913681A (pt) Composição farmacêutica compreendendo entacapona ou nitecapona, assim como um derivado de celulose reticulada
BR0314353A (pt) Compostos, composições farmacêuticas, uso de um ou mais compostos em combinação com outros compostos farmacologicamente ativos, e, método para tratar um paciente que sofre de um distúrbio
BR9813179A (pt) Formulação de liberação prolongada
DK1171101T3 (da) Fremgangsmåde til fremstilling af en vanduoplöselig amorf depotmatrix
TW200518785A (en) Pharmaceutical formulation
BR0206979A (pt) Métodos e composições para reduzir o paladar de agentes farmaceuticamente ativos
BR9912533A (pt) Composição farmacêutica tendo sabor melhorado

Legal Events

Date Code Title Description
B10A Cessation: cessation confirmed